摘要
目的了解2011-2015年呼和浩特市健康人群麻疹抗体水平,评价含麻疹成分疫苗的接种工作质量,为制定消除麻疹策略提供科学依据。方法 2011-2015年每年抽取2~4个县区,每个县区抽取0~6岁、7~12岁、13~19岁、20~29岁、30~岁组5个年龄组的健康人群,每组随机抽取35人,5年共1 573人,应用酶联免疫吸附法检测麻疹IgG抗体。结果 2011-2015年共检测1 573人,其中麻疹IgG抗体阳性1 482人,阳性率94.2%。不同年份间麻疹IgG抗体、不同年龄组间麻疹IgG抗体阳性率差异均有统计学意义(P<0.05),不同地区间麻疹IgG抗体阳性率差异无统计学意义(P>0.05)。结论 2011-2015年呼和浩特市健康人群麻疹IgG抗体水平较高,已建立一定的免疫屏障。但由于30~岁组人群的麻疹抗体水平较低,建议对该年龄组人群开展强化免疫,青少年组开展查漏补种;同时继续加强麻疹监测,努力实现消除麻疹目标。
Objective To understand the measles antibody level of healthy population in Huhhot City and evaluate the quality of the measles vaccination,and provide scientific basis for the measles elimination strategy. Methods Extract randomly 2 ~ 4 counties from Huhhot every year from 2011 to 2015,each country extract five age groups from whole population which contain 0~ 6 years old,7 ~ 12,13 ~ 19 years old,20 ~ 29 years old,over 30 years of age,15 ~ 35 people were extracted from each age group all of about 1 573 people. By using enzyme linked immunosorbent assay to test measles IgG antibody. Results Total tested 1 573 people from 2011 to 2015,which measles IgG antibody positive 1 482 cases,the result showed that the positive rate of measles antibody was 94. 2%. There were statistically significant differences in the positive rates of measles IgG antibody between different years and ages（ P 0. 05）,while the positive rates of measles IgG antibody between different regions had no statistically significant differences（ P 0. 05）. Conclusion The measles antibody level of the Huhhot healthy crowd was higher,and certain immune barrier had been established. But the measles antibody level of over 30 years of age was low,it is suggested to implement measles aggrandizement immunity on the over 30 age and supplementary immunization for the adolescent group,continue to strengthen the measles surveillance to make great efforts to realize the target to eliminate the measles at the same time.
出处
《医学动物防制》
2018年第1期39-41,共3页
Journal of Medical Pest Control
基金
呼和浩特市卫生和计划生育委员会关于2017年麻风疫苗查漏补种活动实施方案项目(呼卫计字[2017]406号)
关键词
麻疹
抗体
监测
Measles
Antibody
Surveillance
